$RGBP @Frontpagestocks Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease SAN DIEGO, January 8, 2019 /PRNewswire/ --
Regen BioPharma, Inc. (RGBP) and (RGBPP), reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company's small molecule therapies for autoimmune disorders, in this case specifically IBD.
IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies available to IBD sufferers.
"Our ex-vivo studies with RG-NAH005 (Regen's small molecule agonist) support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "We believe incorporating CBD in our studies will allow us to potentially strengthen positive outcomes for patients."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.
"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "We are enthusiastic that combining CBD with our small molecule agonist will potentially make our small molecule therapy for IBD more dynamic is its approach to treating this disease."
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
https://finance.yahoo.com/news/regen-biopharm...00199.html
Regen BioPharma, Inc. (RGBP) and (RGBPP), reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company's small molecule therapies for autoimmune disorders, in this case specifically IBD.
IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies available to IBD sufferers.
"Our ex-vivo studies with RG-NAH005 (Regen's small molecule agonist) support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "We believe incorporating CBD in our studies will allow us to potentially strengthen positive outcomes for patients."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.
"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "We are enthusiastic that combining CBD with our small molecule agonist will potentially make our small molecule therapy for IBD more dynamic is its approach to treating this disease."
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
https://finance.yahoo.com/news/regen-biopharm...00199.html
